Wednesday, 11 January 2017

Sensex strong, Nifty inches towards 8400 after banks' earnings

Drug major Lupin has received final approval from the US health regulator to market its Desoximetasone cream, used for treatment of skin disease, in the American market. Lupin said in a BSE filing that it "has received final approval for its Desoximetasone cream USP, 0.05 percent and Desoximetasone cream USP, 0.25 percent from the United States Food and Drug Administration (USFDA)". 

The products to be marketed are generic versions of Taro's Topicort LP Emollient cream, 0.05 percent and Topicort cream, 0.25 percent.

No comments:

Post a Comment